These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 19240100)
21. Keeping the door open to pharma. Harris J Fam Pract Manag; 2009; 16(4):10. PubMed ID: 19630169 [No Abstract] [Full Text] [Related]
22. DRUG PROBLEMS AND THE PHILADELPHIA PLAN. DURANT TM JAMA; 1965 Jun; 192():973-6. PubMed ID: 14290439 [No Abstract] [Full Text] [Related]
23. Closing the door on pharma? A national survey of family medicine residencies regarding industry interactions. Fugh-Berman A; Brown SR; Trippett R; Bell AM; Clark P; Fleg A; Siwek J Acad Med; 2011 May; 86(5):649-54. PubMed ID: 21436662 [TBL] [Abstract][Full Text] [Related]
24. [Auspicious changes are seen in physicians, professional medical societies, and industry relationships]. Ceriani Cernadas JM Arch Argent Pediatr; 2009 Jun; 107(3):195-7. PubMed ID: 19543623 [No Abstract] [Full Text] [Related]
25. Christian medical and dental associations adopt new bioethics statement: medical malpractice. Todays Christ Dr; 2000; 31(3):5. PubMed ID: 12568070 [No Abstract] [Full Text] [Related]
26. Conflict of interest or productive collaboration? The pharma: academic relationship and its implications for headache medicine. Finkel AG Headache; 2006; 46(7):1181-5. PubMed ID: 16866722 [No Abstract] [Full Text] [Related]
27. Medical student exposure to and attitudes about pharmaceutical companies. Soyk C; Pfefferkorn B; McBride P; Rieselbach R WMJ; 2010 Jun; 109(3):142-8. PubMed ID: 20672554 [TBL] [Abstract][Full Text] [Related]
28. MSMS task force identifies priorities with third party payers. Duhamel PA; Adelman SH; Barry JL; Billi JE; Black RW; Bluhm GB; Gordon M; Kolins MD; Margulis RR; Maynard GD Mich Med; 1994 Sep; 93(9):38-9. PubMed ID: 7990729 [No Abstract] [Full Text] [Related]
30. Editorial: Milwaukee Society vs the State Society. Boulanger WJ Wis Med J; 1974 Dec; 73(12):9-10. PubMed ID: 4446625 [No Abstract] [Full Text] [Related]
31. How a marriage with big pharma ended in divorce. Arie S BMJ; 2013 Oct; 347():f6062. PubMed ID: 24103763 [No Abstract] [Full Text] [Related]
32. Tackling conflicts of interest. Industry tie may be benchmark of quality. van Lent M; Out HJ BMJ; 2011 Sep; 343():d5607. PubMed ID: 21896592 [No Abstract] [Full Text] [Related]
33. Unethical business practices in U.S. health care alarm physician leaders. Weber DO Physician Exec; 2005; 31(2):6-13. PubMed ID: 15844791 [TBL] [Abstract][Full Text] [Related]
35. Margaret McCartney: Forever indebted to pharma--doctors must take control of our own education. McCartney M BMJ; 2015 Apr; 350():h1965. PubMed ID: 25869648 [No Abstract] [Full Text] [Related]
37. Tackling conflicts of interest. Two reasons to be cautious when considering bans on industry ties. Smith R BMJ; 2011 Sep; 343():d5606. PubMed ID: 21896591 [No Abstract] [Full Text] [Related]
38. The ethics of pharmaceutical industry gift-giving: the role of a professional association. Morin K; Morse LJ Am J Bioeth; 2003; 3(3):54-5. PubMed ID: 14594494 [No Abstract] [Full Text] [Related]
39. The patient-physician-industry-government partnership: a societal good. Frishman WH Am J Med; 2009 Oct; 122(10):886-7. PubMed ID: 19786152 [No Abstract] [Full Text] [Related]